Paul Karpecki

1 week ago | optometrytimes.com | Paul Karpecki |Emily Kaiser Maharjan

The landscape of myopia management is evolving rapidly, with growing global awareness and an increasing arsenal of treatment options. In a recent discussion on the FDA's acceptance of Sydnexis's NDA submission for SYD-101, a non-compounded atropine drop indicated for myopia, Paul Karpecki, OD, FAAO, emphasized how the perception of myopia has shifted—from a benign refractive error to a serious medical condition with long-term ocular health implications.

4 weeks ago | optometrytimes.com | Paul Karpecki |Emily Kaiser Maharjan

The recent FDA acceptance of the new drug application for atropine 0.01% (SYD-101, Sydnexis) marks a significant milestone in the field of myopia management, and Paul Karpecki, OD, FAAO, clinical investigator of the STAR study. SYD-101 is a low-dose atropine formulation designed to slow the progression of myopia in children.